Wewere able to induce and maintain remission with camostat mesilate, a serine protease inhibitor, in two patients with ulcerative colitis, to whomsalicylazosulfapyridine could not be administered due to previous side effects. The enzymatic activity of proteases from granulocyte, pancreatic juice and bacteria is possibly harmful to the inflammed colonic mucosa. Camostat mesilate can be expected to have an anti-inflammatory effect on the damagedmucosaof inflammatory bowel disease. (Internal Medicine 32: 350-354, 1993) 
Introduction
Ulcerative colitis is a chronic disorder of unknown etiology characterized by inflammation of the colonic mucosa. In the treatment of mild to moderate colitis, salicylazosulfapyridine (SASP) is widely used; adverse reactions, however, are occasionally encountered.
Protease inhibitors are thought to be possible therapeutic agents since their action is exerted on mucosal inflammation. Werecently administered camostat mesilate, a serine protease inhibitor, to two patients with active colitis, whose symptomsresulted in subsidence.
Case Report Case1
In 1987, a 43-year-old male was hospitalized with more than ten episodes of bloody diarrhea and lower abdominal pain daily. Five years previously, at the age of 37, he was first diagnosed as having ulcerative colitis and received medication of SASPfor one year; SASP was then discontinued because of severe nausea. On examination he was undernourished and exhausted but afebrile.
There was marked tenderness in the left lower abdomenand hyperactive bowel sounds. Bacteriological examination of feces showed no pathological finding. Erythrocyte sedimentation rate was 20mm/hr.
Other laboratory data of hematology and biochemistry were all within normal range. Barium enema (Fig. la) week. Hence, a low-residue diet was started and all medicines but camostat mesilate were discontinued.
After 2 months of hospitalization, repeated stool examinations were negative for occult blood, and barium enema ( Fig. 2a ) and colonoscopic examination (Fig. 2b) showed normal findings. His diet was returned to normal.
The sole treatment with camostat mesilate was continued after discharge. He thereby remained in total remission at least for 20 months with visits to the outpatient department.
Case2
In 1990, a 36-year-old male who had been followed up at the outpatient department was hospitalized because of bloody diarrhea with lower abdominal pain two to four
From the Second Department of Internal Medicine, Shiga University of Medical Science Hospital, Seta Received for publication October 28, 1992; Accepted for publication March 16, 1993 Reprint requests should be addressed to Dr. Shigeru Senda, the Second Department of Internal Medicine, Shiga University of Medical Science, Tsukinowa-cho, Seta, Otsu, Shiga 520-21, Japan times a day. Twoyears earlier, the diagnosis of active ulcerative colitis was first made and he was given SASPin a daily dose of 3.0g with a good response. At that time, however, levels of GOT, GPT and alkaline phosphatase became moderately elevated, but returned to normal immediately after SASPwas discontinued. The patient was afebrile and physical examination was unremarkable except for mild tenderness in the lower abdomen. Stool cultures yielded no enteric pathogens.
The white-blood-cell count was 14,800 /A/ml with a slight left shift of the granulocytic series. Other hematological and biochemical examinations were within normal limits.
Barium enema (Fig. 3a) , colonoscopy ( Fig. 3b ) and histological examination of colonic biopsy specimens (Fig. 3c) showed active colitis involving the total colon.
The patient was treated with parenteral nutrition, a low-residue diet and oral administration of camostat mesilate in a daily dose of 600 mg with informed consent. Noother medicine for treatment of ulcerative colitis was used. His symptom of colitis disappeared in a week and occult blood test returned to negative at three weeks after admission. Then, he started to take a normal diet. The follow-up examinations of barium enema (Fig. 4a) and colonoscopy ( Fig. 4b ) revealed marked recovery of colitis. He has continuously received medication of camostat mesilate after discharge, and thus remission has been maintained for 24 months.
Discussion
Wewere able to induce total remission with oral administration of camostat mesilate in our two patients with mild (in case 2) and moderate (in case 1), total ulcerative colitis, for whomSASPcould not be of use due to side effects. After their discharge, remission was maintained by the sole treatment with camostat mesilate during the periods of at least 24 months and 20 months, respectively. In the course of inducing remission, we administered parenteral nutrition and/or a low-residue diet for bowel rest in combination with camostat mesilate therapy. Even though colitis symptomswere relieved to some extent by the state of bowel rest, there was no evidence that nutritional therapy led the patients with ulcerative colitis to total remission (1). It was noteworthy that, in case 1, the initial hospital course was unsatisfactory despite TPN therapy until camostat mesilate was administered. Although the etiology of ulcerative colitis is unknown, the activity of proteases from granulocyte, pancreatic juice and bacteria in colon is respected as a factor exacerbating inflammation in involved mucosal tissue.
Bohe et al (2, 3) hypothesized a local protease-antiprotease imbalance in the pathogenesis of active ulcerative colitis, on the basis of the increasing levels of pancreatic elastase, anionic trypsin and granulocytic elastase in fecal extracts and the decreasing level of alpha2-macroglobulin in plasma from patients with this disease.
They therefore suggested the possible favorable effect of an appropriate protease inhibitor on inflammatory mucosa.
Camostat mesilate, which has been commonlyused for treatment of chronic pancreatitis in Japan (4), inhibits serine proteases, such as trypsin, plasmin, thrombin, kallikrein (5). No serious side effect has been reported even in long-term medication. On the other hand, while the pathogenesis of active ulcerative colitis appeared to be relevant to platelet activating factor (PAF) locally synthesized (6), an in vitro study (7) has indicated that camostat mesilate inhibits elastase release from PAFstimulated granulocytes. Since this drug can be expected to have an anti-inflammatory effect on the intestine as well as on the pancreas, camostat mesilate may be worthwhile as a therapeutic attempt in patients with inflammatory bowel disease (IBD).
Other protease inhibitors such as ulinastatin and gabexate mesilate also have the possibility as therapeutic agents for IBD. Yagita et al (8) 6) Eliakim R, Karmeli F, Razin E, Rachmilewitz D. Role of plateletactivating factor in ulcerative colitis: Enhanced production during active disease and inhibition by sulfasalazine and prednisolone.
